Exactech, Inc. (EXAC) Given Consensus Rating of “Hold” by Analysts
Exactech, Inc. (NASDAQ:EXAC) has been assigned an average recommendation of “Hold” from the seven ratings firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and five have issued a hold rating on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $49.00.
EXAC has been the subject of several recent analyst reports. Robert W. Baird lowered Exactech from an “outperform” rating to a “neutral” rating and set a $42.00 target price for the company. in a report on Monday, October 23rd. ValuEngine lowered Exactech from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Sidoti lowered Exactech from a “buy” rating to a “neutral” rating in a report on Monday, October 23rd. BidaskClub raised Exactech from a “sell” rating to a “hold” rating in a report on Friday, August 18th. Finally, Gabelli lowered Exactech from a “buy” rating to a “hold” rating in a report on Tuesday, October 24th.
Several hedge funds have recently added to or reduced their stakes in EXAC. Dimensional Fund Advisors LP grew its holdings in Exactech by 5.6% during the third quarter. Dimensional Fund Advisors LP now owns 874,161 shares of the medical equipment provider’s stock valued at $28,803,000 after purchasing an additional 46,400 shares during the period. Gamco Investors INC. ET AL bought a new position in Exactech during the second quarter valued at $18,463,000. Vanguard Group Inc. grew its holdings in Exactech by 1.6% during the second quarter. Vanguard Group Inc. now owns 415,253 shares of the medical equipment provider’s stock valued at $12,375,000 after purchasing an additional 6,594 shares during the period. FMR LLC grew its holdings in Exactech by 51.6% during the second quarter. FMR LLC now owns 251,876 shares of the medical equipment provider’s stock valued at $7,506,000 after purchasing an additional 85,709 shares during the period. Finally, Teton Advisors Inc. grew its holdings in Exactech by 7.7% during the second quarter. Teton Advisors Inc. now owns 250,373 shares of the medical equipment provider’s stock valued at $7,461,000 after purchasing an additional 17,900 shares during the period. 66.30% of the stock is owned by institutional investors.
Exactech (NASDAQ:EXAC) last released its earnings results on Monday, October 30th. The medical equipment provider reported $0.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.03). The business had revenue of $61.40 million during the quarter, compared to the consensus estimate of $61.78 million. Exactech had a net margin of 0.18% and a return on equity of 7.22%. equities research analysts anticipate that Exactech will post 1.29 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This story was posted by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2017/12/14/exactech-inc-exac-given-consensus-rating-of-hold-by-analysts.html.
Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.
Receive News & Ratings for Exactech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech and related companies with MarketBeat.com's FREE daily email newsletter.